[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-metastases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,77,100,123,144,166,194,219,243,268,290,314],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100483460","randomized-trial-on-same-day-sbrt-and-surgical-stabilization-for-symptomatic-spinal-metastases-100483460",false,"NCT05575323","Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases","Stereotactic Body Radiotherapy and pedicLE Screw fixatioN During One Hospital Visit for Patients With Painful Unstable Spinal Metastases: A Randomized Trial (BLEND)","BLEND","Inclusion Criteria:\n\n* Symptomatic (cervical, thoracic and\u002For lumbar) spinal metastases from solid tumors and (impending) spinal instability requiring radiotherapy and surgical decompression and\u002For stabilization\n* Histologic proof of malignancy or radiographic\u002Fclinical characteristics indicating malignancy beyond reasonable doubt\n* Radiographic evidence of spinal metastases\n* Participation in PRESENT cohort, including consent for randomization into future trials\n* Fit for (radio)surgery\n* Age \\>18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* SBRT cannot be delivered, e.g. in patients who cannot lie on the treatment table because of pain\n* Routine surgical decompression and\u002For stabilization and radiotherapy cannot be performed, e.g., multiple spinal metastases requiring surgical bridging of more than five vertebral levels and\u002For requiring radiotherapy on more than one location\n* Prior surgery or radiotherapy to the index level(s)\n* Multiple myeloma\n* Neurological deficits (ASIA C, B or A), or partial neurological deficits (ASIA D) with rapid progression (hours to days)\n* Treated with Bevacizumab and other medication with long half-life that interferes with radiotherapy\n* Life expectancy of less than 3 months","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The BLEND RCT aims to evaluate the (cost-)effectiveness of same-day SBRT and surgical stabilization with or without decompression for the treatment of symptomatic, unstable spinal metastases on physical functioning four weeks after the start of treatment, compared with the standard of care (surgery followed by radiotherapy as soon as the wound healed sufficiently).",[27],"Spinal Metastases",[29,30,31,32,33],"Spinal metastases","SBRT","Surgery","Same-day treatment","RCT","RECRUITING","2026-05-04",{"date":37,"type":38},"2026-05-08","ACTUAL",{"date":40,"type":38},"2022-10-15",{"date":42,"type":21},"2027-06-30",{"name":44,"class":45},"UMC Utrecht","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100633530","the-effect-of-radiotherapy-after-separation-surgery-for-spinal-metastases-100633530","NCT07527884","The Effect of Radiotherapy After Separation Surgery for Spinal Metastases","Postoperative Radiotherapy Versus No Radiotherapy Following Separation Surgery for Spinal Metastases: A Mixed Cohort Study","Inclusion Criteria:\n\n1. Age over 18 years old, gender not limited;\n2. The patient has undergone separation surgery within 3 weeks;\n3. The pathological result of the separation surgery site of the patient indicates that the lesion is a metastatic tumor, and the primary lesion is located outside the spine;\n4. The expected survival period is ≥ 6 months;\n5. The patient has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with poor general condition and those who are intolerant to radiotherapy, chemotherapy, and targeted therapy;\n2. Patients whose treatment segments have not received any other surgical treatment or radiotherapy;\n3. Patients who participated in other clinical trials of drugs or medical devices within 3 months before enrollment;\n4. Other situations judged by the investigator as making the subject unsuitable for enrollment.",{"count":55,"type":21},130,[24],"The aim of this clinical study is to explore the impact of whether radiotherapy is administered after spinal metastasis surgery on the prognosis and survival of patients, to describe the clinical outcomes, and to optimize future clinical decisions.",[27,59,60,61],"Spinal Tumor","Radiotherapy","Separation Surgery",[63,64,65,66],"spinal metastases","spinal tumor","radiotherapy","separation surgery","NOT_YET_RECRUITING","2026-04-09",{"date":70,"type":38},"2026-04-14",{"date":72,"type":21},"2026-05-01",{"date":74,"type":21},"2028-06-30",{"name":76,"class":45},"Shanghai Changzheng Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100484565","comparing-sbrt-to-crt-in-patients-with-spinal-metastases-100484565","NCT05589701","Comparing SBRT to CRT in Patients With Spinal Metastases","Prospective Registry Trail COMparing Stereotactic Body Radiotherpy (SBRT) to Conventional PAlliative RadioTherapy (CRT) in Patients With Spinal Metastases","COMBAT","Inclusion Criteria:\n\n* Adults 18 years of age or older.\n* Patients seen at the Princess Margaret Cancer Centre with painful spinal metastases amenable to radiation treatment.\n* Confirmation of diagnosis: a) Known\u002Fdocumented prior histological cancer diagnosis\n* Able to provide written consent\n* ECOG performance status 0-3\n\nExclusion Criteria:\n\n* Prior radiotherapy, with fields overlapping, resulting in excessive doses to organs at risk\n* Lymphoma, myeloma or germ cell malignancies","100 Years",{"count":20,"type":21},"2 Years","OBSERVATIONAL","This is a single institutional registry-based, prospective, observational study to describe radiation oncologists' decision making during evaluation of patients and to compare real-world outcomes of SBRT vs CRT.\n\nA registry-based trial involves observing the effect of something without manipulating it.",[27],"2026-03-03",{"date":93,"type":38},"2026-03-05",{"date":95,"type":38},"2022-12-12",{"date":97,"type":21},"2027-12",{"name":99,"class":45},"University Health Network, Toronto",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100625960","sbrt-technique-implementation-for-spinal-metastases-irradiation-100625960","NCT07429422","SBRT Technique Implementation for Spinal Metastases Irradiation","Program SBRT Technique Implementation in Spinal Metastases Irradiation","Inclusion Criteria:\n\n* Adult patients (≥18 years) with spinal metastases or spinal tumors referred for stereotactic body radiotherapy (SBRT).\n* Patients eligible for SBRT treatment according to the institutional SBRT spine protocol.\n* Ability to undergo CT simulation, immobilization, and image-guided radiotherapy procedures.\n\nExclusion Criteria:\n\n* Inability to tolerate SBRT positioning or immobilization.\n* Clinical situations requiring urgent surgical intervention or alternative treatment.\n* Other medical conditions that prevent safe SBRT delivery.",{"count":20,"type":21},[24],"Stereotactic body radiotherapy (SBRT) is a highly precise, image-guided radiotherapy technique delivering 1-5 high-dose fractions to spinal metastases. Compared with conventional radiotherapy, SBRT enables delivery of a higher biologically effective dose while maintaining high precision.\n\nThe Institute of Oncology Ljubljana initiated spinal SBRT treatments in 2017 and introduced an institutional SBRT spine protocol in 2019. As SBRT is technically demanding, strict adherence to standardized planning and delivery procedures is essential to ensure treatment quality and patient safety.\n\nThis clinical program aims to support structured implementation and continuous development of the institutional SBRT spine protocol in routine clinical practice. The study prospectively evaluates treatment-related toxicity and local tumor control following SBRT for spinal metastases in order to monitor treatment safety and effectiveness within the institutional program.",[27,111,112],"Spinal Tumors","Bone Metastases","2026-02-20",{"date":115,"type":38},"2026-02-24",{"date":117,"type":38},"2021-11-01",{"date":119,"type":21},"2026-12-31",{"name":121,"class":45},"Institute of Oncology Ljubljana",2,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":46},"100558203","d20054litt-for-spine-tumors-100558203","NCT06548061","D20054;LITT for Spine Tumors","Single Center Observational Study Using Spinal Laser Interstitial Thermal Therapy (sLITT) in the Treatment of Spine Metastases and Tumors","Inclusion Criteria:\n\n1. Histology confirmed spinal tumor involving the T2-T12 spine segments.\n2. Indication for spine stereotactic radiosurgery or palliative intervention.\n3. Normal neurologic exam at the time of presentation (Frankel grade E).\n\nExclusion Criteria:\n\n1. Contraindication to MRI\n2. ANY neurologic deficit\n3. Tumor spanning more than 3 consecutive vertebral segments\n4. Contraindication to general anesthesia\n5. Pregnancy",{"count":131,"type":21},25,[24],"The objective of this clinical study is to evaluate the efficacy and safety of spinal laser interstitial therapy in the treatment of metastatic spinal tumors. The investigators hypothesize that rates of local tumor control are comparable between conventional open surgical techniques and spinal laser interstitial therapy.",[27],"2026-02-04",{"date":137,"type":38},"2026-02-06",{"date":139,"type":38},"2024-05-16",{"date":141,"type":21},"2029-06-01",{"name":143,"class":45},"Dartmouth-Hitchcock Medical Center",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":46},"100603384","preoperative-stereotactic-radiotherapy-for-treatment-of-spinal-metastases-100603384","NCT07135817","Preoperative Stereotactic Radiotherapy for Treatment of Spinal Metastases","PRESTRASM","Inclusion Criteria:\n\n* Indication for surgical treatment of a spinal tumor\n* Age: older or 18 years\n* Estimated survival \\> 6 months\n* The patient is able to understand the nature, significance and scope of the clinical study in the context of patient information and to base the decision to participate in the study on this.\n\nExclusion Criteria:\n\n* Age: \\\u003C 18 years\n* Motor deficit or loss of bladder and bowel control that urges an emergency surgical decompression\n* Tumor extent does not allow hypofractioned SBRT (1-3 fractions)",{"count":152,"type":21},20,[24],"The goal of this interventional clinical trial is to evaluate the efficacy and safety of preoperative hypofractionated Stereotactic Body Radiotherapy (SBRT) in the treatment of patients undergoing surgery for spinal metastases.\n\nThe main questions this study aims to answer are:\n\n* Does preoperative SBRT result in local tumor control at the involved spinal segments as assessed by MRI\u002FCT scan at 3 and 6 months postoperatively?\n* What are the postoperative outcomes in terms of pain intensity, functional status and quality of life?\n\nParticipants will receive hypofractionated SBRT to spinal metastases shortly before surgical intervention.\n\nParticipants will undergo preoperative and follow-up assessments, including:\n\n* MRI and CT scans before and after surgery and at 3 and 6 months after surgery to measure tumor size\n* Pain questionnaires where patients rate their current pain, worst pain, and average pain in the last 24 hours on a scale from 0 (no pain) to 10 (worst pain imaginable)\n* A short questionnaire (Karnofsky Performance Status) to assess the patient's general ability to carry out daily activities\n* Several patient questionnaires to evaluate back pain, physical limitations, and overall quality of life (Oswestry Disability Index, EORTC QLQ-C30, and EORTC QLQ-BM22)",[27,156],"Solid Tumor Cancer","2025-08-15",{"date":159,"type":38},"2025-08-22",{"date":161,"type":38},"2025-08-01",{"date":163,"type":21},"2027-01",{"name":165,"class":45},"University Medical Center Goettingen",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":46},"100529409","phase-3-comparing-single--vs-multi-fraction-spine-stereotactic-radiosurgery-in-spinal-metastases-100529409","NCT06173401","Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases","A Randomized Phase III TriaL Comparing SingLe- Versus Multi-Fraction Spine STereotActic Radiosurgery for Patients With Spinal Metastases (ALL-STAR)","Inclusion Criteria:\n\n* Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer Age ≥ 18 years\n* Patients who have cervical, thoracic, or lumbar spine metastasis that need treatment.\n* Patients will have 1 to 3 separate spinal sites that require treatment.\n* Each spinal site to be treated on trial will span 1-2 contiguous vertebral levels\n* ECOG 0-2\n* Negative serum or urine pregnancy test within 14 days prior to enrollment for people of childbearing potential or who are not postmenopausal\n* people of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control\n* Ability to understand and the willingness to sign (personally or by a legal authorized representative) the written IRB approved informed consent document\n\nExclusion Criteria:\n\n* Prior or planned radiation off study within or overlapping with study treatment site\n* Inability to have either an MRI or a CT scan. Patients with pacemaker will be allowed to undergo CT instead of MRI\n* Pediatric patients (age \\\u003C18 years old), pregnant women, and nursing patients will be excluded\n* Histology's of myeloma or lymphoma\n* Patients with strength 1-3 (of 5), bladder incontinence, bowel incontinence, and\u002For bladder retention that is associated with spinal site to be treated\n* Prior surgery to spinal site intended to be treated with protocol SRS\n* Excluded those with SINS 13-18",{"count":174,"type":21},274,[176],"PHASE3","The goal of this study is to determine whether fractionated Stereotactic radiosurgery (SRS) for spine metastases is associated with improved local tumor control compared to single-fraction SRS. Patients will be randomized to treatment with spine SRS using either 22 Gy in 1 fraction or 28 Gy in 2 fractions.",[27],[180,181,182,183,184],"spine stereotactic radiosurgery","cervical","lumbar","thoracic","metastases","2025-07-15",{"date":187,"type":38},"2025-07-16",{"date":189,"type":38},"2023-12-18",{"date":191,"type":21},"2028-12",{"name":193,"class":45},"Stanford University",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":46},"100381130","phase-2-trial-of-combined-radiotherapy-and-vertebroplasty-for-patients-with-painful-metastatic-spinal-lesions-100381130","NCT04242589","Trial of Combined Radiotherapy and Vertebroplasty for Patients With Painful Metastatic Spinal Lesions","A Phase II Randomized Trial of Combined Radiotherapy and Vertebroplasty to Improve the Quality of Life of Patients With Painful Metastatic Localized Spinal Lesions","Inclusion Criteria:\n\n1. Participants capable of giving informed consent, or if appropriate, participants having an acceptable individual capable of giving consent on the participant's behalf\n2. Patients must be 18 years of age or older\n3. Spinal vertebral metastases confirmed by CT, MRI or bone scan.\n4. Patients with painful (VAS of at least ≥ 2) vertebral spinal metastases in the thoracic and \u002For lumbar spine (not cervical).\n5. Patients must be willing and able to comply with schedule visits, treatment plan, tests and other study procedures\n6. Life expectancy \\> 6 months. Life expectancy will be evaluated by the study investigator both clinically and by using Linden model. Patient should be in the group B or C of the Linden model.\n7. Patients with an ECOG score 0-2 or Karnofsky performance status of ≥ 60% will be eligible for enrolment (see appendix 1).\n8. No prior EBRT to the target +\u002F-1 vertebral body level\n9. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. In addition, females under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level \\> 40 mIU\u002FmL to confirm menopause\n10. Patients of childbearing \u002F reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly (Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard) .\n11. Females must not breastfeed during study treatment.\n12. Male patients should agree to not donate sperm during study treatment.\n13. Absence of any condition hampering compliance with study protocols and follow-up schedule; those conditions should be reviewed with the patient prior to trial registration\n\nExclusion Criteria\n\n1. Patient cannot provide consent\n2. Prior radiotherapy to the target +\u002F-1 vertebral body level\n3. Life expectancy \\\u003C 6 months (assessed both clinically and using Linden model)\n4. Karnofsky performance status of \\\u003C 60%\n5. Primary bone tumors\n6. Plasmacytoma\n7. Communicated fracture\n8. Associated Impending cord compression or spinal cord compression\n9. Epidural involvement",{"count":202,"type":21},64,[204],"PHASE2","Since patients with spinal metastases are living longer, durable palliation with long-term tumor control are becoming increasingly important.\n\nEBRT results in durable local control of bone metastasis. However, about 25 % of patients with spinal metastases only achieved complete pain relief following EBRT for a median duration of less than 4 months. This could be partly due to spinal instability. In addition, almost half of the patients who receive EBRT will subsequently develop VCFs . Hence, RT does not stabilize the spine secondary to VCFs and is not effective in preventing imminent VCFs. Vertebroplasty has rapidly reduced pain and improved function in patients with VCFs. However, vertebroplasty does not provide local tumor control similar to EBRT.\n\nIt is theorized that combining vertebroplasty with EBRT will stabilize the spine, relieve the pain, prevent imminent VCFs and minimize or avoid the need for opioids. It is hypothesized that combining a spine stabilization procedure such as vertebroplasty with RT will be the most effective management for patients with spinal metastases than RT alone for patients with spinal metastases. Combined vertebroplasty and radiotherapy is not a standard treatment option at present. This study is designed to quantify the advantage of adding vertebroplasty to radiotherapy for patients with spinal metastases. If the study is proven to be significant, it could become the standard of care for patients with spinal metastases.",[27],[208,209,60],"Vertebroplasty","Vertebral Compression Fracture","2025-06-24",{"date":212,"type":38},"2025-06-26",{"date":214,"type":38},"2021-03-03",{"date":216,"type":21},"2027-11-01",{"name":218,"class":45},"AHS Cancer Control Alberta",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":240,"leadSponsor":241,"locationsCount":46},"100574192","evaluate-the-efficacy-of-radiofrequency-ablationvertebroplasty-with-or-without-sbrt-for-treating-painful-spinal-vertebral-metastases-100574192","NCT06756087","Evaluate the Efficacy of Radiofrequency Ablation\u002FVertebroplasty with or Without SBRT for Treating Painful Spinal Vertebral Metastases","Radiofrequency Ablation\u002FVertebroplasty Versus Radiofrequency Ablation\u002FVertebroplasty Combined with SBRT for Painful Spinal Vertebral Metastases: a Multicenter, Practical, Randomized, Controlled, Non-Inferiority Clinical Study","Inclusion Criteria:\n\n1. The subject voluntarily participates in this study, and both the patient and their family sign an informed consent form. The subject demonstrates good compliance and cooperates with follow-up.\n2. Age 18 or older, no gender restrictions.\n3. The target population for this trial consists of patients with bone metastases from malignant tumors confirmed by pathology or imaging, with lesions located between T5 and L5. The number of affected vertebral sites is fewer than three, and the lesions are mainly osteolytic, affecting primarily the vertebral bodies.\n4. Expected survival is greater than three months.\n5. Initial diagnosis with an NPRS pain score \\> 3.\n6. ECOG performance status score of 0-2.\n7. The function of vital organs meets the following requirements: a) Adequate bone marrow function: WBC ≥ 3.0×10\\^9\u002FL; absolute neutrophil count (ANC) ≥ 1.5 ×10\\^9\u002FL; lymphocyte count ≥ 6.0×10\\^8\u002FL; platelet count ≥ 50×10\\^9\u002FL, with no blood transfusion within 14 days prior to the first cellular therapy; hemoglobin ≥ 10.0 g\u002FdL. b) Adequate liver and kidney function: total bilirubin ≤ 2.0×ULN, AST and ALT \\\u003C 2.5×ULN; serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 ml\u002Fmin (calculated using the Cockcroft-Gault formula). c) Coagulation function: INR ≤ 1.5×ULN, APTT ≤ 1.5×ULN. d) Adequate cardiovascular function: left ventricular ejection fraction (EF) ≥ 50%, QTcF interval ≤ 450 ms for males and ≤ 470 ms for females.\n8. Use of at least one medically approved contraceptive method (e.g., surgical sterilization, oral contraceptives, intrauterine device, abstinence, or barrier methods with spermicide) for at least six months.\n\nExclusion Criteria:\n\n1. Subjects with no measurable lesions;\n2. Known brain metastasis and\u002For clinically suspected brain metastasis (subjects with asymptomatic brain metastasis or clinically stable brain metastasis for more than three months after local treatment can be included);\n3. Subjects whose target lesions received radiotherapy within the past two years;\n4. Tumor types sensitive to radiotherapy, including malignant lymphoma, testicular seminoma, Wilms tumor, neuroblastoma, medulloblastoma, Ewing sarcoma, and small cell tumors.\n5. Spinal metastases involving spinal appendages, destruction of the posterior wall of the vertebral canal, or compression of the spinal dura mater;\n6. Subjects preparing for or who have previously undergone tissue\u002Forgan transplantation;\n7. Subjects with active infections or unexplained fever \\>38.5℃ during screening or before treatment;\n8. Patients with active pulmonary tuberculosis (TB), currently receiving anti-TB treatment or treated for TB within the past year before screening;\n9. Positive syphilis serology test;\n10. Known history of HIV-positive test or known acquired immunodeficiency syndrome (AIDS);\n11. Active hepatitis B: hepatitis B surface antigen (HBsAg) positive with HBV DNA levels exceeding 10,000 IU\u002Fml; hepatitis C: hepatitis C antibody (HCV Ab) positive with HCV RNA levels exceeding 1,000 IU\u002Fml; co-infection with hepatitis B and hepatitis C;\n12. Cardiovascular disease meeting any of the following: a. Congestive heart failure with NYHA classification ≥ III; b. Severe arrhythmia requiring medication; c. Acute myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, or stenting within six months before initial dosing; d. Left ventricular ejection fraction (LVEF) \\\u003C 50%; e. QTcF interval \\> 450 ms for males and \\> 470 ms for females, or risk factors for torsades de pointes, such as clinically significant hypokalemia, family history of long QT syndrome, or familial arrhythmias (e.g., Wolff-Parkinson-White syndrome) as determined by the investigator;\n13. Uncontrolled hypertension (defined as systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg despite standardized antihypertensive treatment);\n14. Subjects deemed by the investigator to have serious uncontrolled diseases or other conditions that may affect participation in the study or render them unsuitable for study treatment.",{"count":227,"type":21},120,[24],"This study is a prospective, multicenter, open, practical, randomized controlled, non inferiority effect clinical study initiated by researchers, which aims to evaluate the clinical efficacy and safety of radiofrequency ablation\u002Fvertebroplasty and radiofrequency ablation\u002Fvertebroplasty combined with SBRT in the treatment of painful spinal metastases. This study plans to include about 120 cases in about 3 research centers nationwide, including the Department of bone oncology of Shanghai First People's Hospital (main center, 60 cases), the Department of bone oncology of the Third Affiliated Hospital of Southern Medical University (sub center 1, 30 cases), and the Department of bone oncology of Peking University People's Hospital (sub center 2, 30 cases). The patient was diagnosed with spinal metastasis of malignant tumor and had pain of more than 3 points. The subjects with spinal metastasis located at t5-l5 were selected for clinical research. All patients were treated with RFA\u002FPVA minimally invasive surgery. In principle, no more than 2 vertebral bodies were treated. All patients will receive MRI\u002FCT examination of the affected spine within 6 weeks before enrollment to determine the degree of spinal involvement. All patients were randomly divided into experimental group and control group after minimally invasive surgery, the ratio was 1:1. The patients in the experimental group recovered to the original system treatment about two weeks after minimally invasive surgery; The control group began to receive SBRT radiotherapy of the surgical vertebral body in about two weeks, and the radiotherapy time was two weeks. According to the recommendations of the Department of radiotherapy, SBRT radiotherapy should use any of the following dose and grading scheme: 4 times 24gy, 5 times 30Gy, 6 times 36Gy, 7 times 42GY. The patients in the two groups were followed up after treatment, and evaluated at 1, 2 and 4 weeks and 3, 6 and 12 months after treatment. The NRPS pain degree and pafi pain function comprehensive score were evaluated, and the local lesions were evaluated at 1, 3, 6 and 12 months after operation. To evaluate the local control of spinal metastases, pain improvement and quality of life changes of the two treatment strategies.",[27,231,232],"Local Control","Pain Cancer",[63,234,235],"Radiofrequency Ablation","Stereotactic radiotherapy","2024-12-24",{"date":238,"type":38},"2025-01-01",{"date":238,"type":21},{"date":119,"type":21},{"name":242,"class":45},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":46},"100534856","the-safety-and-efficacy-of-autologous-transfusion-in-spinal-surgery-for-lung-cancer-with-spinal-metastasis-100534856","NCT06244264","The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis","A Single-center, Prospective, Randomized Controlled Study of the Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis","Inclusion Criteria:\n\n* The age range is 18-75 years old;\n* The pathological diagnosis was lung cancer and spinal metastatic tumor;\n* Expected survival \\> 3 months, can tolerate surgery;\n* Unstable spine; And\u002For spinal cord nerve compression, nerve function; Progressive decline, palliative spinal open decompression surgery\n* Patients with intraoperative\u002Fpostoperative Hb\\\u003C90 g\u002FL or other conditions requiring blood transfusion\n\nExclusion Criteria:\n\n* Serious heart dysfunction or heart failure, diagnosed blood system diseases, coagulation disorders;\n* Severe renal insufficiency or need hemodialysis treatment;\n* Sepsis or septicemia;\n* Unable to obtain consent from the patient or family.","75 Years",{"count":252,"type":21},118,[24],"The goal of this single-center prospective randomized controlled trial is to test and compare the safety and effectiveness of autologous blood transfusion in spinal surgery for lung cancer spinal metastases. The main questions it aims to answer are:\n\n* Does autologous blood transfusion increase the incidence of new metastases?\n* Does autologous blood transfusion affect postoperative hemoglobin levels and the number of circulating tumor cells in the blood?\n* Can autologous blood transfusion reduce the rate of allogeneic transfusion during and after surgery for spinal metastases?",[27,256,257,31,258],"Blood Transfusion Complication","Lung Cancer","Autologous Blood Transfusion","2024-07-11",{"date":261,"type":38},"2024-07-12",{"date":263,"type":38},"2024-03-15",{"date":265,"type":21},"2027-12-31",{"name":267,"class":45},"Guangdong Provincial People's Hospital",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":275,"enrollmentInfo":276,"targetDuration":277,"studyType":88,"phases":4,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":46},"100428788","sbrt-in-the-management-of-solid-spinal-metastases-100428788","NCT04863612","SBRT in the Management of Solid Spinal Metastases","The Efficiency of SBRT in Preventing Recurrent Spinal Cord Compression in Patients Undergoing Surgery and Radiotherapy for Epidural Spinal Metastasis From Solid Tumor","Inclusion Criteria:\n\n* Radiological diagnosis of spinal metastasis from solid tumor with epidural imminent or actual spinal cord compression, with or without neurological deficits. Patients will be scheduled for surgery + SBRT. If contra-indications preclude surgery and only SBRT is performed, patients will still be included.\n* Written informed consent to participate in the study must be obtained from the subject or proxy \u002Flegal representative\n* Males and females \\> 18 years\n\nExclusion Criteria:\n\n* Any concomitant condition or disease which, in the opinion of the investigator, would affect the reliability of the collected data.\n* Patients that had previous radiotherapy on the index spinal level without the possibility for additional SBRT at that particular level.","99 Years",{"count":20,"type":21},"5 Years","Documenting efficiency of SBRT in the management of epidural spinal metastases from solid tumors",[280,27],"Extradural Tumor","2023-12-28",{"date":283,"type":38},"2023-12-29",{"date":285,"type":38},"2021-05-18",{"date":287,"type":21},"2036-03-01",{"name":289,"class":45},"Universitaire Ziekenhuizen KU Leuven",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":297,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":298,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":46},"100525337","en-bloc-resection-versus-separation-surgery-combined-with-radiotherapy-for-the-treatment-of-spinal-oligometastatic-tumor-100525337","NCT06120426","En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.","En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor-A Multi-center, Prospective, Randomized, Controlled Study.","Inclusion Criteria:\n\n* 1\\) Be able to sign written informed consent.\n* 2\\) Age range from 18 to 75 years old, regardless of gender.\n* 3\\) Within conservative treatment, the patient still has uncontrollable pain, metastatic cancer lesions that still progress, spinal instability\u002Fpotential instability, or symptoms of spinal cord\u002Fnerve compression.\n* 4\\) After the patient underwent Positron Emission Tomography-Computed Tomography (PET-CT) examination, it was indicated that there were no more than 3 metastatic organs and no more than 5 metastatic lesions in the whole body of cancer. Among them, there was at least 1 spinal metastasis and at most 5 spinal metastases.\n* 5\\) Imaging examinations (enhanced MRI, enhanced CT, X-ray) indicate the presence of spinal metastasis.\n* 6\\) The expected survival period is ≥ 6 months.\n* 7)No other surgical contraindications\n\nExclusion Criteria:\n\n* 1\\) Primary tumors of the spine or multiple tumors of the body, with\\>3 metastatic organs and\\>5 metastatic sites.\n* 2\\) Previously underwent spinal surgery, or received radiotherapy for the responsible segment of this treatment.\n* 3\\) Severe heart, lung, liver, kidney or other diseases affecting the surgery.\n* 4\\) Having cognitive impairment, sensory aphasia, and inability to understand basic instructions.\n* 5\\) Participated in clinical trials of other drugs or medical devices within 3 months prior to enrollment.\n* 6\\) Infectious diseases.\n* 7\\) Refuse to follow up or participate.\n* 8\\) The researchers determine that the patients are not suitable for enrollment this clinical trail.",true,{"count":299,"type":21},182,"The purpose of this clinical trial is to explore the impact of En bloc surgery and separation surgery combined with radiation therapy on the prognosis and survival of patients with spinal oligometastatic cancer, describe the clinical results, and optimize future treatment goals",[27,59,60,302,31],"Malignant Bone Tumor",[304,305],"Total enbloc spondylectomy","Oligometastases","2023-11-09",{"date":308,"type":38},"2023-11-13",{"date":310,"type":38},"2023-07-01",{"date":312,"type":21},"2027-07-01",{"name":76,"class":45},{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":17,"minAge":321,"maxAge":250,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":337,"locationsCount":46},"100523297","intraoperative-radiotherapy-in-treating-spinal-metastases-100523297","NCT06093854","Intraoperative Radiotherapy in Treating Spinal Metastases","The Efficacy and Safety of Intraoperative Radiotherapy Vesus Stereotactic Body Radiotherapy in Managing Spinal Metastases: A Prospective, Single-center, Open-label, Non-inferior, Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical diagnosis of spinal metastases;\n* Estimated survival time more than 3 months;\n* The spinal instability neoplastic score (SINS) \\>12;\n* The general condition allows to recieve surgery;\n* Single or multiple metastatic lesions with only one site presenting epidural spinal cord compression;\n* signed informed consent.\n\nExclusion Criteria:\n\n* Clinical diagnosis of primary spinal tumors;\n* Presence of metastases in central nerve system;\n* Isolated lesion undergoing en bloc resection;\n* Mental disorder and\u002For intellectual dificiency;\n* Refusing to accept follow-up;\n* without signing informed consent.","35 Years",{"count":323,"type":21},132,[24],"In order to provide theoretical evidence for the comprehensive and standardized treatment of spinal metastases with pathological fractures and\u002For spinal cord compression, the investigators conduct this trial to investigate the efficacy and safety of IORT and postoperative SBRT in adjuvant treatment of metastatic spinal tumors after posterior decompression surgery by recruiting patients with spinal metastases who met the inclusion criteria, and randomly divided them into the following treatment cohorts: 1) decompression surgery + IORT (15-20 Gy, 20-50min）; 2) decompression surgery and postoperative SBRT(30Gy, 5 fractions, 3 weeks).",[27],[63,328,329,330],"intraoperative radiotherapy","stereotactic body radiotherapy","decompression surgery","2023-10-20",{"date":333,"type":38},"2023-10-23",{"date":335,"type":21},"2024-01",{"date":163,"type":21},{"name":76,"class":45}]